ClinicalTrials.gg
CompletedNCT06423352Updated Apr 30, 2026Results posted

A Study to Evaluate Zilebesiran in Japanese Patients With Mild to Moderate Hypertension

A Phase 1/2 interventional study of Zilebesiran and Placebo in Mild to Moderate Hypertension, sponsored by Alnylam Pharmaceuticals. Completed at 3 sites in Japan. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-30.

Sponsored by Alnylam Pharmaceuticals · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 142 studies in Hypertension with a site in Japan — 11 open to participants now, 17 under way, 8 of them phase 3. Hypertension · Japan.

Enrollment
105th of 125
36 · median 237
Started
2024
with 4 others
Phase 1/2
2 of 142
none open now
Registered
127th of 142
by date

Among the 142 studies in Hypertension with a site in Japan, this one is the 105th largest by enrollment of the 125 interventional ones that give a count, is one of 5 that started in 2024, is one of 2 in phase 1/2, and was the 127th registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.

Browse Hypertension studies →

Open to participants now

11 of the 142 studies in Hypertension with a site in Japan are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 142 studies in Hypertension with a site in Japan, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety, tolerability, efficacy, pharmacodynamics (PD) and pharmacokinetics (PK) of zilebesiran in Japanese patients with mild to moderate hypertension.

03

Conditions studied

  • Mild to Moderate Hypertension

Browse trials for

Keywords

  • High blood pressure
  • Hypertension
  • Hypertensive
  • siRNA
  • Angiotensinogen
  • AGT
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must have been born in Japan, and their biological parents and grandparents must have been of Japanese origin
  • Has mean systolic office blood pressure (SBP) of >130 and \<=165 mmHg by automated office blood pressure measurement, after a minimum of 3 weeks of washout if taking hypertensive medication
  • Has 24-hour mean SBP ≥130 mmHg by ambulatory blood pressure monitoring (ABPM), without antihypertensive medication

Exclusion criteria

Exclusion Criteria:

  • Has secondary hypertension, symptomatic orthostatic hypotension
  • Has (ALT) or aspartate aminotransferase (AST) >2× (ULN)
  • Has elevated serum potassium >5 mmol/L
  • Has estimated (eGFR) of \<60 mL/min/1.73m\^2
  • Has received an agent within the last 30 days
  • Has Type 1 diabetes mellitus, poorly controlled Type 2 diabetes mellitus or newly diagnosed Type 2 diabetes mellitus
  • Has history of intolerance to SC injection(s)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Zilebesiran

    Participants will be administered a single dose of zilebesiran.

    Drug: Zilebesiran

  • Placebo comparator
    Placebo

    Participants will be administered a single dose of placebo.

    Drug: Placebo

Interventions

  • Zilebesiran administered by subcutaneous (SC) injection

    Also known as: ALN-AGT01

  • DrugPlacebo

    Placebo administered by SC injection

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events (AEs)

    An AE is any untoward medical occurrence in a patient or clinical investigational subject administered a medicinal product and which does not necessarily have a causal relationship with this treatment.

    Time frame: Up to 12 months

Secondary outcomes

  1. Percent Change From Baseline in Serum Angiotensinogen (AGT) at Month 3 and Month 6

    Time frame: Baseline and Month 3 and Month 6

  2. Change From Baseline at Month 3 and Month 6 in 24-hour Mean SBP and DBP Assessed by ABPM

    Time frame: Baseline and Month 3 and Month 6

  3. Change From Baseline at Month 3 and Month 6 in SBP and DBP Assessed by OBP

    Time frame: Baseline and Month 3 and Month 6

  4. Maximum Plasma Concentration (Cmax) of Zilebesiran and Its Metabolite

    Cmax is the highest concentration of zilebesiran in the plasma and metabolite after a dose is given.

    Time frame: Predose and 30 minutes, 1, 2, 3, 4, 6, 8, 12, 16, 24 and 48 hours post-dose.

  5. Time to Maximum Plasma Concentration (Tmax) of Zilebesiran and Its Metabolite

    Tmax is the time it takes for zilebesiran to reach the Cmax after administration.

    Time frame: Predose and 30 minutes, 1, 2, 3, 4, 6, 8, 12, 16, 24 and 48 hours post-dose.

  6. Elimination Half-life (t1/2) of Zilebesiran and Its Metabolite

    t½ is the time it takes for the concentration of the drug in the plasma to be reduced by 50%.

    Time frame: Predose and 30 minutes, 1, 2, 3, 4, 6, 8, 12, 16, 24 and 48 hours post-dose.

  7. Area Under the Curve (AUClast) of Zilebesiran and Its Metabolite

    AUClast is the AUC from the time of dosing to the last measurable concentration of the drug.

    Time frame: Predose and 30 minutes, 1, 2, 3, 4, 6, 8, 12, 16, 24 and 48 hours post-dose.

  8. Pooled Urine PK (fe) of Zilebesiran and Its Metabolite

    Time frame: Predose and 2 to 6, 6 to 12, and 12 to24 hours post-dose.

07

Results

Posted Apr 30, 2026

Participant flow

Participants with mild to moderate hypertension were enrolled at three (3) sites in Japan.

6-month Double-blind (DB) Period
Participant flow — 6-month Double-blind (DB) Period
MilestoneZilebesiran 300 mgZilebesiran 600 mgPlacebo
Started121212
Completed111112
Not completed110
Withdrew: Withdrawal by subject110
6-month Safety Follow-up Period
Participant flow — 6-month Safety Follow-up Period
MilestoneZilebesiran 300 mgZilebesiran 600 mgPlacebo
Started111112
Completed111112
Not completed000

Outcome measures

PrimaryNumber of Participants With Adverse Events (AEs)

An AE is any untoward medical occurrence in a patient or clinical investigational subject administered a medicinal product and which does not necessarily have a causal relationship with this treatment.

Time frame:
Up to 12 months
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs)
ParticipantsZilebesiran 300 mgZilebesiran 600 mgPlacebo
Treatment-emergent AEs, n (%)664
Related Treatment-emergent AEs, n (%)011
Treatment-emergent SAEs, n (%)000
Severe Treatment-emergent AEs, n (%)000
Treatment-emergent AEs Leading to Withdrawal from Study, n (%)000
Death (any fatal SAE), n (%)000
SecondaryPercent Change From Baseline in Serum Angiotensinogen (AGT) at Month 3 and Month 6
Time frame:
Baseline and Month 3 and Month 6
Reported as:
Mean · Percent Change
Percent Change From Baseline in Serum Angiotensinogen (AGT) at Month 3 and Month 6
Percent ChangeZilebesiran 300 mgZilebesiran 600 mgPlacebo
Month 3 (% Change from Baseline)-96.85 ± 1.45-96.85 ± 2.326.93 ± 21.93
Month 6 (% Change from Baseline)-95.36 ± 2.17-95.79 ± 3.21-2.74 ± 12.75
SecondaryChange From Baseline at Month 3 and Month 6 in 24-hour Mean SBP and DBP Assessed by ABPM
Time frame:
Baseline and Month 3 and Month 6
Reported as:
Mean · mmHg
Change From Baseline at Month 3 and Month 6 in 24-hour Mean SBP and DBP Assessed by ABPM
mmHgZilebesiran 300 mgZilebesiran 600 mgPlacebo
Month 3 SBP (Change from Baseline)-15.2 ± 9.0-17.8 ± 11.80.4 ± 7.8
Month 6 SBP (Change from Baseline)-12.6 ± 4.8-12.2 ± 11.7-6.5 ± 11.0
Month 3 DBP (Change from Baseline)-8.6 ± 6.0-9.2 ± 6.50.3 ± 5.3
Month 6 DBP (Change from Baseline)-7.1 ± 2.4-8.2 ± 6.0-3.9 ± 6.6
SecondaryChange From Baseline at Month 3 and Month 6 in SBP and DBP Assessed by OBP
Time frame:
Baseline and Month 3 and Month 6
Reported as:
Mean · mmHg
Change From Baseline at Month 3 and Month 6 in SBP and DBP Assessed by OBP
mmHgZilebesiran 300 mgZilebesiran 600 mgPlacebo
Month 3 SBP (Change from Baseline)-14.4 ± 21.0-14.4 ± 12.34.4 ± 5.0
Month 6 SBP (Change from Baseline)-10.3 ± 12.9-6.8 ± 9.61.2 ± 13.3
Month 3 DBP (Change from Baseline)-7.8 ± 10.4-7.4 ± 8.00.1 ± 5.2
Month 6 DBP (Change from Baseline)-4.5 ± 7.9-1.7 ± 6.8-2.2 ± 7.1
SecondaryMaximum Plasma Concentration (Cmax) of Zilebesiran and Its Metabolite

Cmax is the highest concentration of zilebesiran in the plasma and metabolite after a dose is given.

Time frame:
Predose and 30 minutes, 1, 2, 3, 4, 6, 8, 12, 16, 24 and 48 hours post-dose.
Reported as:
Geometric mean · nanograms per milliliter (ng/mL)
Maximum Plasma Concentration (Cmax) of Zilebesiran and Its Metabolite
nanograms per milliliter (ng/mL)Zilebesiran 300 mgZilebesiran 600 mg
Zilebesiran Plasma PK1024 ± 53.52445 ± 42.4
Metabolite [AS(N-1)3'] Plasma PK101.4 ± 72.1288.2 ± 49.7
SecondaryTime to Maximum Plasma Concentration (Tmax) of Zilebesiran and Its Metabolite

Tmax is the time it takes for zilebesiran to reach the Cmax after administration.

Time frame:
Predose and 30 minutes, 1, 2, 3, 4, 6, 8, 12, 16, 24 and 48 hours post-dose.
Reported as:
Median · Hours
Time to Maximum Plasma Concentration (Tmax) of Zilebesiran and Its Metabolite
HoursZilebesiran 300 mgZilebesiran 600 mg
Zilebesiran Plasma PK3.53 (1.00 to 12.0)6.00 (1.00 to 16.0)
Metabolite [AS(N-1)3'] Plasma PK8.01 (3.00 to 16.0)16.00 (4.00 to 16.0)
SecondaryElimination Half-life (t1/2) of Zilebesiran and Its Metabolite

t½ is the time it takes for the concentration of the drug in the plasma to be reduced by 50%.

Time frame:
Predose and 30 minutes, 1, 2, 3, 4, 6, 8, 12, 16, 24 and 48 hours post-dose.
Reported as:
Geometric mean · Hours
Elimination Half-life (t1/2) of Zilebesiran and Its Metabolite
HoursZilebesiran 300 mgZilebesiran 600 mg
Zilebesiran Plasma PK5.83 ± 65.35.56 ± 36.9
Metabolite [AS(N-1)3'] Plasma PK9.42 ± 120.85.48 ± 25.6
SecondaryArea Under the Curve (AUClast) of Zilebesiran and Its Metabolite

AUClast is the AUC from the time of dosing to the last measurable concentration of the drug.

Time frame:
Predose and 30 minutes, 1, 2, 3, 4, 6, 8, 12, 16, 24 and 48 hours post-dose.
Reported as:
Geometric mean · ng*h/mL
Area Under the Curve (AUClast) of Zilebesiran and Its Metabolite
ng*h/mLZilebesiran 300 mgZilebesiran 600 mg
Zilebesiran Plasma PK16150 ± 43.541260 ± 32.2
Metabolite [AS(N-1)3'] Plasma PK1587 ± 73.84906 ± 47.5
SecondaryPooled Urine PK (fe) of Zilebesiran and Its Metabolite
Time frame:
Predose and 2 to 6, 6 to 12, and 12 to24 hours post-dose.
Reported as:
Geometric mean · Percent
Pooled Urine PK (fe) of Zilebesiran and Its Metabolite
PercentZilebesiran 300 mgZilebesiran 600 mg
Zilebesiran Urine PK23.62 ± 21.230.08 ± 16.1
Metabolite [AS(N-1)3'] Urine PK2.68 ± 42.73.85 ± 28.3

Adverse events

Collected over Up to 12 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Zilebesiran 300 mg0/12 (0%)0/12 (0%)6/12 (50%)
Zilebesiran 600 mg0/12 (0%)0/12 (0%)6/12 (50%)
Placebo0/12 (0%)0/12 (0%)4/12 (33.3%)
Most frequent other events
Showing 10 of 17
Most frequent other events
EventZilebesiran 300 mgZilebesiran 600 mgPlacebo
InfluenzaInfections and infestations0/122/120/12
PharyngitisInfections and infestations2/120/120/12
HeadacheNervous system disorders2/121/120/12
Eye pruritusEye disorders0/121/120/12
GastralgiaGastrointestinal disorders0/120/121/12
NauseaGastrointestinal disorders0/120/121/12
COVID-19Infections and infestations1/120/121/12
Alanine aminotrasferase increasedInvestigations1/120/120/12
Blood alkaline phosphatase increasedInvestigations0/121/120/12
Blood potassium increasedInvestigations0/121/120/12

Baseline characteristics

Safety Analysis Set (SAS): All participants who received any amount of study drug. All by-treatment analyses based on the Safety Analysis Set were grouped according to the treatment actually received.

Age, Categorical
Age, Categorical(Participants)Zilebesiran 300 mgZilebesiran 600 mgPlaceboTotal
Age category (years), n (%) — <=18 years0000
Age category (years), n (%) — Between 18 and 65 years129930
Age category (years), n (%) — >=65 years0336
Age, Continuous
Age, Continuous(Years)Zilebesiran 300 mgZilebesiran 600 mgPlaceboTotal
Median58.5 (20 to 64)54.5 (38 to 70)58.5 (50 to 66)58 (20 to 70)
Sex: Female, Male
Sex: Female, Male(Participants)Zilebesiran 300 mgZilebesiran 600 mgPlaceboTotal
Sex (male or female), n (%) — Female65112
Sex (male or female), n (%) — Male671124
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Zilebesiran 300 mgZilebesiran 600 mgPlaceboTotal
Race, n (%) — American Indian or Alaska Native0000
Race, n (%) — Asian12121236
Race, n (%) — Native Hawaiian or Other Pacific Islander0000
Race, n (%) — Black or African American0000
Race, n (%) — White0000
Race, n (%) — More than one race0000
Race, n (%) — Unknown or Not Reported0000
24-hour Mean Blood Pressure by Ambulatory Blood Pressure Monitoring (ABPM)
24-hour Mean Blood Pressure by Ambulatory Blood Pressure Monitoring (ABPM)(millimeters of mercury (mmHg))Zilebesiran 300 mgZilebesiran 600 mgPlaceboTotal
Baseline Systolic Blood Pressure (SBP; Actual)143.6 ± 12.2138.9 ± 8.0137.7 ± 6.8140.1 ± 9.4
Baseline Diastolic Blood Pressure (DBP; Actual)87.2 ± 8.286.6 ± 8.285.6 ± 5.486.4 ± 7.2
Mean Office Blood Pressure (OBP)
Mean Office Blood Pressure (OBP)(mmHg)Zilebesiran 300 mgZilebesiran 600 mgPlaceboTotal
Baseline SBP (Actual)139.8 ± 11.5134.3 ± 9.4133.9 ± 8.5136 ± 10
Baseline DBP (Actual)88.3 ± 7.486.6 ± 8.389.2 ± 6.388 ± 7.3
08

Study locations

3 sites
  • Clinical Trial Site
    Fukuoka, Japan
  • Clinical Trial Site
    Osaka, Japan
  • Clinical Trial Site
    Tokyo, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Access to Anonymized individual participant data that support these results is made available 12 months after study completion and not less than 12 months after the product and indication have been approved in the US and/or the EU. Access to data may be declined where there is likelihood a patient could be identified or other feasibility issue, where there is a potential conflict of interest, a planned business activities or an actual or potential competitive risk. Data will be provided contingent upon the approval of a research proposal and the execution of a data sharing agreement. Timeframes for data access may vary and can take up to 6 months or more. Requests for access to data can be submitted via the website www.vivli.org. Questions can also be directed to datasharing@alnylam.com.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2024 to primary completion in Jul 2025, 13 months.

Results were first posted in Apr 2026, 9 months after primary completion.

Of 21 phase 1/2 interventional studies under Hypertension, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 60. This study's 13 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2024
First posted
May 21, 2024
StartActual
Jun 5, 2024
Primary completionActual
Jul 17, 2025
CompletionActual
Jul 17, 2025
Results first posted
Apr 30, 2026
Last update
Apr 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06423352
Responsible party
Sponsor
First posted
May 21, 2024
Start date
Jun 5, 2024
Primary completion
Jul 17, 2025
Completion
Jul 17, 2025
Results posted
Apr 30, 2026
Last update
Apr 30, 2026

Study contacts

Medical Director
study director · Alnylam Pharmaceuticals

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zilebesiran

Start the discussion